SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295

A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295


  • Org Study ID: GU17-295
  • Secondary ID:
  • NCT ID: NCT03737123
  • NCT Alias:
  • Sponsor: Nabil Adra - Other
  • Source: Hoosier Cancer Research Network

Brief Summary

This is a single arm phase II study assessing the activity of atezolizumab in combination with carboplatin + gemcitabine or docetaxel compared to historical controls of chemotherapy only in metastatic or recurrent urothelial carcinoma subjects. Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.

Overal Status Start Date Phase Study Type
Recruiting December 19, 2018 Phase 2 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Progression Free Survival (PFS)

Primary Outcome 1 - Time Frame: 18 months

Condition:

  • Urothelial Carcinoma

Eligibility

Criteria:
Inclusion Criteria:

- Written informed consent and HIPAA authorization for release of personal health
information prior to registration. NOTE: HIPAA authorization may be included in the
informed consent or obtained separately.
r/> - Age ≥ 18 years at the time of consent.

- ECOG Performance Status of 0-2 within 28 days prior to registration.

- Histological or cytological confirmed metastatic or unresectable locally advanced
urothelial carcinoma (primary tumor: renal pelvis, ureters, urinary bladder, or
urethra).

- Patients with mixed histologies are eligible.

- Cisplatin ineligible at the time of diagnosis with metastatic urothelial carcinoma
based on consensus definition with any of the following criteria: ECOG PS 2,
creatinine clearance < 60mL/min, CTCAE v4 grade ≥ 2 hearing loss, CTCAE v4 grade ≥ 2
peripheral neuropathy, New York Heart Association (NYHA) class ≥ 3 heart failure.

- Measurable disease according to RECIST 1.1 within 28 days prior to registration.

- Must have had progressive metastatic disease after previous treatment with PD-1 or
PD-L1 inhibitor (in the adjuvant or metastatic setting). Treatment regimen will be
determined based on prior treatment:

- PD1 or PDL1 inhibitor with no prior platinum chemotherapy for metastatic disease.
These patients should be treated with atezolizumab + carboplatin + gemcitabine on
trial.

- Sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen. These
patients should be treated with atezolizumab + docetaxel on trial.

- Most recent therapy does not have to have been a checkpoint inhibitor. Intercurrent
treatment is acceptable if subjects meet all other inclusion criteria.

- A subject with prior brain metastasis may be considered if they have completed their
treatment for brain metastasis at least 4 weeks prior to study registration, have been
off of corticosteroids for ≥ 2 weeks, and are asymptomatic.

- Previous neoadjuvant or adjuvant chemotherapy that was completed 6 months prior to
study enrollment is allowed.

- REQUIRED archival tumor tissue (prior to treatment with single agent PD-1 or PD-L1
inhibitor) must be identified prior to registration and obtained during the screening
period. Confirmation of acquisition should occur prior to C1D1 treatment.
Unavailability of tissue will render the subject ineligible for study. Biopsy should
be excisional, incisional or core needle. Fine needle aspiration is insufficient.
Sample requirement is FFPE block + 1 H&E stained slide or 25 unstained slides + 1 H&E
stained slide.

- Demonstrate adequate organ function as defined in the table below. All screening labs
to be obtained within 28 days prior to registration.

- White blood cell (WBC) ≥ 2 k/mm3

- Absolute Neutrophil Count (ANC) ≥ 1.5 K/mm3

- Hemoglobin (Hgb) ≥ 9 g/dL

- Platelet >100k

- Estimated creatinine clearance ≥ 30 mL/min

- Bilirubin 1.5 ≤ (ULN)

- Aspartate aminotransferase (AST) ≤ 1.5 × ULN

- Alanine aminotransferase (ALT) ≤ 1.5 × ULN

- International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial
Thromboplastin Time (aPTT) ≤ 2 × ULN (Note: This applies only to patients who are
not receiving therapeutic anticoagulation; patients receiving therapeutic
anticoagulation should be on a stable dose)

- Females of childbearing potential (FOCBP) must have a negative serum pregnancy test
within 28 days prior to registration. These women must also have a negative serum or
urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within
24 hours prior to the start of atezolizumab then every 6 weeks thereafter. NOTE:
Females are considered of child bearing potential unless they are surgically sterile
(have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)
or is post-menopausal. Menopause is defined clinically as 12 months of amenorrhea in a
woman over 45 in the absence of other biological or physiological causes. In addition,
women under the age of 62 must have a documented serum follicle stimulating hormone
(FSH) level less than 40 mIU/mL.

- Females of childbearing potential and males must be willing to abstain from
heterosexual activity or to use 2 forms of effective methods of contraception from the
time of informed consent until 150 days (5 months) after treatment discontinuation.
The two contraception methods can be comprised of two barrier methods, or a barrier
method plus a hormonal method.

- Men who are sexually active with FOCBP must use any contraceptive method with a
failure rate of less than 1% per year. Men receiving atezolizumab and who are sexually
active with WOCBP will be instructed to adhere to contraception for a period of 150
days (5 months) after the last dose of investigational product.

- As determined by the enrolling physician or protocol designee, ability of the subject
to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

- Previous autoimmune complication from PD-1 or PD-L1 inhibitor requiring permanent
discontinuation of therapy.

- Previous permanent discontinuation from PD-1 or PD-L1 inhibitor due to an adverse
event (patients who had temporary holds or discontinuation of PD-1 or PD-L1 inhibitor
and then re-treated are eligible).

- Any serious or uncontrolled medical disorder or active infection that would impair the
ability of the subject to receive protocol therapy.

- Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
mother is being treated on study).

- 5. Has a known additional malignancy that is progressing or required treatment ≤ 48
months of study registration. Exceptions: include malignancies with negligible risk of
metastasis or death treated with expected curative outcome or undergoing surveillance
per investigator's discretion (such as adequately treated carcinoma in situ of the
cervix, basal or squamous cell skin cancer, ductal carcinoma in situ treated
surgically with curative intent, or very low risk or low risk prostate cancer per NCCN
guidelines).

- Active central nervous system (CNS) metastases. Subjects with brain metastases are
eligible if metastases have been treated and there is no magnetic resonance imaging
(MRI) evidence of progression within 28 days prior to the first dose of atezolizumab
administration. There must also be no requirement for immunosuppressive doses of
systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks
prior to study drug administration.

- Treatment with any investigational drug within 30 days prior to registration.

- Subjects with an active or recent history of a known or suspected autoimmune disease
or recent history of a syndrome that required systemic
corticosteroids/immunosuppressive medications EXCEPT for syndromes which would not be
expected to recur in the absence of an external trigger. (Subjects with vitiligo,
autoimmune thyroiditis, or type I diabetes mellitus are permitted to enroll.).

- As there is potential for hepatic toxicity with atezolizumab, drugs with a
predisposition to hepatoxicity should be used with caution in subjects treated with
atezolizumab-containing regimen.

- Subjects should be excluded if they have known history of testing positive for
hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV
antibody) indicating acute or chronic infection. Testing is not required.

- Subjects should be excluded if they have known history of testing positive for human
immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
Testing is not required.

- History of allergy to atezolizumab or respective chemotherapy regimen (carboplatin +
gemcitabine or docetaxel).
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Nabil Adra, MD

Role: Principal Investigator

Affiliation: Indiana University Melvin and Bren Simon Cancer Center

Overall Contact

Name: Nabil Adra, MD

Phone: 317-948-6942

Email: nadra@iu.edu

Locations

Facility Status Contact
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana 46202
United States
Recruiting Nabil Adra, MD
317-948-6942
nadra@iu.edu
Nebraska Methodist Hosptial
Omaha, Nebraska 68114
United States
Recruiting Craig Ryan
402-354-7938
craig.ryan@nmhs.org